Selank vs Semax: Research Comparison

Selank and Semax are the two best-known Russian-origin nootropic peptides. Both are short heptapeptides delivered intranasally in research, but their parent peptide origins (tuftsin vs ACTH) drive distinct primary endpoints.

Mechanism of Action

Selank is a synthetic heptapeptide (tuftsin analog). Selank is derived from tuftsin and studied for anxiolytic, immunomodulatory, and GABAergic effects. It has shown influence on BDNF expression and enkephalin metabolism in research models.

Semax is a synthetic heptapeptide (ACTH 4-10 analog). Semax is derived from the ACTH 4-10 fragment and studied primarily for nootropic and neuroprotective effects. It influences BDNF, NGF, and dopaminergic signaling in research models.

Technical Comparison

| Parameter | Selank | Semax | |---|---|---| | Class | synthetic heptapeptide (tuftsin analog) | synthetic heptapeptide (ACTH 4-10 analog) | | Mechanism | Selank is derived from tuftsin and studied for anxiolytic, immunomodulatory, and GABAergic effects. | Semax is derived from the ACTH 4-10 fragment and studied primarily for nootropic and neuroprotective effects. | | Half-life (research models) | Short plasma half-life; biological effects extend beyond clearance | Short plasma half-life; intranasal route bypasses first-pass metabolism | | Typical research dosing | 250–500 mcg intranasal, divided doses | 200–600 mcg intranasal, divided doses |

Comparative Findings

Selank research emphasizes anxiolytic effects with minimal sedation, immunomodulation, and influence on enkephalin metabolism. Semax research emphasizes cognitive endpoints — attention, memory consolidation, and neuroprotection in ischemic models. Both share BDNF upregulation as a downstream signal.

When Researchers Choose Selank

Researchers select Selank when investigating anxiolytic mechanisms, immune-neural crosstalk, or GABA-adjacent peptide pharmacology.

When Researchers Choose Semax

Researchers select Semax when studying cognitive enhancement, neuroprotection (especially ischemia models), or dopaminergic/BDNF signaling.

Combination Research

Stacked Selank + Semax research is common in nootropic study designs because their primary endpoints (anxiolysis vs cognition) are non-overlapping while sharing complementary BDNF effects.

Frequently Asked Questions

Are intranasal doses interchangeable?

Volumetrically yes, but the pharmacological targets differ. Researchers should not substitute one for the other without redesigning the endpoint.

Which has stronger neuroprotection data?

Semax has the larger published neuroprotection dataset, particularly in stroke and ischemia research models.

Research-Use Disclosure

All content is provided strictly for laboratory research purposes. Compounds discussed are not for human or veterinary consumption. Selank and Semax are research chemicals and have not been approved by the FDA for any therapeutic indication.